Other Events ·
At the 2026 Annual Meeting of Stockholders, Verrica Pharmaceuticals Inc. stockholders approved the Amended and…
VRCAVerrica Pharmaceuticals Inc.
At the 2026 Annual Meeting of Stockholders, Verrica Pharmaceuticals Inc. stockholders approved the Amended and Restated 2018 Equity Incentive Plan, which became effective immediately. The meeting results included the election of Paul B. Manning and Lawrence Eichenfield to the Board of Directors, the advisory approval of executive officer compensation, and the ratification of KPMG LLP as the independent auditor. Out of 17,178,786 shares outstanding, 81.89% of shares were present or represented by proxy. Verrica Pharmaceuticals Inc. is a biopharmaceutical company that develops and commercializes commercial-stage products for skin diseases.